BR9909480A - Método para gerar uma resposta à célula t citotóxica de um especìfico hiv em um hospedeiro - Google Patents

Método para gerar uma resposta à célula t citotóxica de um especìfico hiv em um hospedeiro

Info

Publication number
BR9909480A
BR9909480A BR9909480-0A BR9909480A BR9909480A BR 9909480 A BR9909480 A BR 9909480A BR 9909480 A BR9909480 A BR 9909480A BR 9909480 A BR9909480 A BR 9909480A
Authority
BR
Brazil
Prior art keywords
host
generating
hiv
cytotoxic
cell
Prior art date
Application number
BR9909480-0A
Other languages
English (en)
Inventor
Charles D Y Sia
Pele Chong
Michel H Klein
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Publication of BR9909480A publication Critical patent/BR9909480A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"MéTODO PARA GERAR UMA RESPOSTA à CéLULA T CITOTóXICA DE UM ESPECìFICO HIV EM UM HOSPEDEIRO". Método para gerar uma resposta à célula T citotóxica de um específico HIV em um hospedeiro, que envolve uma administração inicial de uma molécula auxiliadora T ao hospedeiro, a fim de preparar as células auxiliadoras T do sistema imunológico do hospedeiro e uma administração subseq³ente ao hospedeiro de uma mistura da molécula auxiliadora T e uma célula T, que induz a molécula derivada HIV, a gerar uma resposta à célula T específica de HIV no hospedeiro.
BR9909480-0A 1998-04-07 1999-04-01 Método para gerar uma resposta à célula t citotóxica de um especìfico hiv em um hospedeiro BR9909480A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/055,744 US20010019714A1 (en) 1998-04-07 1998-04-07 Hiv-specific cytotoxic t-cell responses
PCT/CA1999/000287 WO1999051267A1 (en) 1998-04-07 1999-04-01 Hiv-specific cytotoxic t-cell responses

Publications (1)

Publication Number Publication Date
BR9909480A true BR9909480A (pt) 2001-10-16

Family

ID=21999878

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909480-0A BR9909480A (pt) 1998-04-07 1999-04-01 Método para gerar uma resposta à célula t citotóxica de um especìfico hiv em um hospedeiro

Country Status (8)

Country Link
US (1) US20010019714A1 (pt)
EP (1) EP1067963A1 (pt)
JP (1) JP3996349B2 (pt)
AU (1) AU759183B2 (pt)
BR (1) BR9909480A (pt)
CA (1) CA2324983A1 (pt)
NZ (1) NZ507742A (pt)
WO (1) WO1999051267A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12016844B2 (en) 2019-07-02 2024-06-25 Virago Vax Inc. Mammary tumor virus suppression
US12029783B2 (en) 2019-07-02 2024-07-09 Virago Vax Inc. Mammary tumor virus vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE320444T1 (de) * 1991-08-26 2006-04-15 Scripps Research Inst Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren
WO1993003764A1 (en) * 1991-08-26 1993-03-04 Cytel Corporation Hla-restricted hepatitis b virus ctl epitopes
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6024965A (en) * 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
US7105164B1 (en) * 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses

Also Published As

Publication number Publication date
NZ507742A (en) 2003-11-28
CA2324983A1 (en) 1999-10-14
US20010019714A1 (en) 2001-09-06
JP3996349B2 (ja) 2007-10-24
EP1067963A1 (en) 2001-01-17
JP2002510650A (ja) 2002-04-09
WO1999051267A1 (en) 1999-10-14
AU759183B2 (en) 2003-04-10
AU3022099A (en) 1999-10-25

Similar Documents

Publication Publication Date Title
NO20025621L (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
BR0009580A (pt) Composição, processos para preparar vìrus da influenza, para preparar um veìculo de liberação de genes, para preparar vìrus da influenza defeituosos de replicação infecciosa, para imunizar um paciente contra um patógeno, para preparar vìrus infeccioso, e para preparar vìrus, vìrus, célula, vetor, célula hospedeira, e, uso do vìrus
GR3034204T3 (en) Lipopolyamines as transfection agents and pharmaceutical uses thereof
UY27552A1 (es) 17a- alquil- 17b- oxi-estratrienos y productos intermediarios para su preparacinn, uso de los 17a-alquil-17b-oxi-estratrienos para obtener medicamentos y preparados farmacéuticos.
HK1142093A1 (en) Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
BR9911163A (pt) Formulação de vacina, formulação farmacêutica, vìrus atenuado de influenza, processos para vacinar um indivìduo, para prevenir uma doença infecciosa em um indivìduo, e, para tratar ou prevenir tumores em um indivìduo
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
ITRM920590A0 (it) Sistema per la realizzazione distrutture in fibra di carbonio, e procedimento per detto, particolarmente idoneo per applicazioni aeronautiche.
ES2194989T3 (es) Composicion adminstrada por via oral, que comprende una toxina de zonula occludens y un agente que tiene una actividad biologica, y su utilizacion.
BRPI9809791B8 (pt) compostos imuno efetores de fosfato de aminoalquil glucosamina e composições compreendendo os mesmos
ZA936629B (en) Potentiation of immunogenic response
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
BRPI0409761A (pt) complexo de um composto farmacêutico, formulação oral, derivado de fosfatidila de um composto farmacêutico, método para a preparação de um derivado de fosfato de um composto farmacêutico, derivado de fosfato de um composto farmacêutico e uso do mesmo
AU5658196A (en) Method for pharmaceutical delivery
YU166790A (sh) Kompleksi koji imaju pomoćnu aktivnost
BR9915215A (pt) Composição farmacêutica para liberação modificada de sensibilizador de insulina
ATE234082T1 (de) Adenosin enthaltendes arzneimittel
DK0737069T3 (da) Deuterede aktive stoffer til transdermal administrering
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
BR9909480A (pt) Método para gerar uma resposta à célula t citotóxica de um especìfico hiv em um hospedeiro
DE69912827D1 (de) "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen
DE59708495D1 (de) Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung
DE69804766D1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
BG104452A (en) New derivatives of the methylenebisphosphonic acid
BR0013574A (pt) Antìgeno vacina de moraxella

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 (IX), 11 E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.